Hepatitis B is a viral illness that is transmitted through blood and other body fluids. Both acute and chronic stages occur, with the frequency of progression to chronicity declining with age at time of infection. Chronic hepatitis B often leads to cirrhosis and hepatocellular carcinoma. Hepatitis B is a vaccine-preventable disease.
Limitations: • The results determined by different assays from different manufacturers can vary due to differences in assay specificities and cannot be used interchangeably. • Assay performance characteristics have not been established in pregnant women or in populations of immunocompromised or immunosuppressed patients. • This assay does not differentiate between a vaccine-induced immune response and an immune response induced by infection with HBV. To determine if the anti-HBs response is due to vaccine or HBV infection, a Total anti-Hepatitis B Core assay may be performed. • This assay is not intended for use in screening blood or plasma donors. • A positive anti-HBs result does not exclude co-infection by another hepatitis virus.
Non-Immune: NON-REACTIVE (<10.0 mIU/mL)
Immune: REACTIVE (>=10.0 mIU/mL)
The presence of hepatitis B surface antibody is consistent with a resolved hepatitis B infection of unknown duration. A result of a single hepatitis B lab study should be interpreted with caution.
Hepatitis B surface antibody can be measured to determine if vaccination is needed or, following a vaccination regimen, to determine if protective immunity has been achieved.
Hepatitis B Surface Ab
Hep. B Surf Antibody (HBsAb)